简介:
- 作者: Suin Jo, Lijin Li, Chandrani Thakur, Kevin A. Telfer, Hussein Sultan, Ray A. Ohara, Michelle He, Giri Nam, Jing Chen, Feiya Ou, Monia Draghi, Nicholas M. Valiante, Robert D. Schreiber, Gwendalyn J. Randolph, Naresha Saligrama, Theresa L. Murphy, William E. Gillanders & Kenneth M. Murphy
- 杂志: Nature
- Doi: https://www.doi.org/10.1038/s41586-026-10353-6
- 出版日期: 2026/4/15
摘要
Vaccines composed of mRNA and lipid nanoparticles (LNPs) activate B cells and T cells by inducing in vivo production of specific protein antigens. While B cells can be activated directly by antigens, T cell activation requires antigen processing and presentation by MHC molecules on specialized antigen-presenting cells (APCs). In response to viral infections, tumours, and protein- and cDNA-based vaccines, antigen presentation to CD8+ T cells is particularly dependent on type 1 conventional dendritic (cDC1) cells, which are specialized for efficient cross-presentation of exogenous antigens1,2,3,4. However, whether similar mechanisms have a role in mRNA–LNP vaccination is unclear. Here we report that mRNA–LNP vaccines do not require cDC1 cells or the WDFY4-dependent cross-presentation pathway for CD8+ T cell priming but instead engage both cDC1 and cDC2 cells redundantly. While CD8+ T cells primed exclusively by either cDC1 or cDC2 cells showed phenotypic differences, both could mediate anti-tumour responses and memory formation. Importantly, acquisition by cDCs of peptide–MHC-I complexes from non-haematopoietic cells, called cross-dressing, provides a substantial component of CD8+ T cell priming, in a manner dependent on type I interferon. mRNA–LNP induction of cross-dressing might explain their ability to activate CD8+ T cells against antigens not encoded by the vaccine.
关于派真
作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IIT、IND及BLA的各个阶段。
凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。